title: Healthy volunteers and early phases of clinical experimentation.
abstract: The main goal of early phase trials is to gain knowledge about the clinical suitability of novel compounds, without pursuing specific therapeutic purposes. Healthy volunteers usually represent the ideal model for conducting phase I clinical trials, in order to investigate pharmacokinetics and pharmacodynamics as well as to document safety and tolerability without interference by concomitant pathological conditions. The increasing cost of novel drug development, in conjunction with ethical considerations, has fostered a new procedure for first-in-man trials, designated as "phase 0," which is conducted very early on a limited number of healthy volunteers who are exposed to low drug levels. The present review discusses issues concerning the enrollment of healthy volunteers in the early phase of drug development from different points of view, with some focus on the Italian experience. From the ethical standpoint, much discussion revolves around payments to healthy volunteers. Most authors agree that an adequate remuneration must be provided to healthy subjects, while avoiding coercion and excessive psychological pressure. Pending the lack of international and national guidelines, our center for clinical drug experimentation has implemented an operative procedure to estimate payments for healthy volunteers based on specific items, including restriction, time spent, discomfort, and risk. Other unresolved issues about the recruitment of healthy volunteers are represented by the lack of international consensus on the definition of healthy status and the need for guidelines about advertisement on clinical trials addressed to potential participants.
authors.affiliation: Clinical Pharmacology Centre for Drug Experimentation Pisa University Hospital, Via Roma 67, 56100, Pisa, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pasqualetti
authors.forename: Giovanni
authors.initials: G
authors.lastname: Gori
authors.forename: Corrado
authors.initials: C
authors.lastname: Blandizzi
authors.forename: Mario
authors.initials: M
authors.lastname: Del Tacca
mesh_terms: D002986:Clinical Trials as Topic / Q000191:economics / Q000941:ethics / Q000379:methods*; D017408:Guidelines as Topic; D006304:Health Status; D006801:Humans; D018579:Patient Selection / Q000941:ethics*; D035842:Research Subjects / Q000191:economics*
references.citation: Bioethics. 1999 Apr;13(2):114-30
references.pmid: 11657095
references.citation: J Med Philos. 2009 Feb;34(1):68-90
references.pmid: 19190076
references.citation: Ann Intern Med. 2002 Mar 5;136(5):368-73
references.pmid: 11874309
references.citation: J Med Ethics. 2008 Sep;34(9):e14
references.pmid: 18757614
references.citation: Am J Bioeth. 2001 Spring;1(2):66-7
references.pmid: 11951901
references.citation: J Clin Pharmacol. 2005 Oct;45(10):1123-36
references.pmid: 16172177
references.citation: Eur J Clin Pharmacol. 1989;36(6):549-50
references.pmid: 2776816
references.citation: Clin Cancer Res. 2007 Feb 1;13(3):783-4
references.pmid: 17289866
references.citation: Contemp Clin Trials. 2005 Jun;26(3):365-75
references.pmid: 15911470
references.citation: J Med Ethics. 2004 Jun;30(3):293-8
references.pmid: 15173366
references.citation: Monash Bioeth Rev. 2005 Jan;24(1):70-4
references.pmid: 16007758
references.citation: IRB. 2003 Sep-Oct;25(5):17-20
references.pmid: 14870741
references.citation: Lancet. 2006 Oct 14;368(9544):1387-91
references.pmid: 17046471
references.citation: J R Coll Physicians Lond. 1986 Oct;20(4):243-57
references.pmid: 3772845
references.citation: J Am Med Inform Assoc. 2005 Nov-Dec;12(6):608-13
references.pmid: 16049231
references.citation: Clin Med Res. 2007 Jun;5(2):91-7
references.pmid: 17607043
references.citation: Br J Clin Pharmacol. 2009 Jul;68(1):34-42
references.pmid: 19660001
references.citation: Eur J Cancer. 2009 Mar;45(5):728-9
references.pmid: 19231159
references.citation: Bioethics. 1997 Oct;11(5):390-6
references.pmid: 11655118